Cambridge Investment Research Advisors, Inc. Reata Pharmaceuticals Inc Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 13, 2023	BUY	$79.22 - $105.37 $173,650 - $230,971	2,192 New	2,192 $223,000
Q4 2021 Feb 03, 2022	SELL	$25.61 - $110.96 $61,156 - $264,972	-2,388 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$100.0 - $143.02 $9,400 - $13,443	94 Added 4.1%	2,388 $240,000
Q2 2021 Aug 10, 2021	BUY	$78.27 - $151.29 $5,244 - $10,136	67 Added 3.01%	2,294 $324,000
Q1 2021 May 07, 2021	BUY	$94.25 - $132.81 $7,728 - $10,890	82 Added 3.82%	2,227 $222,000
Q4 2020 Feb 04, 2021	SELL	$102.03 - $184.62 $20,406 - $36,924	-200 Reduced 8.53%	2,145 $265,000
Q3 2020 Oct 29, 2020	SELL	$93.53 - $163.34 $14,029 - $24,501	-150 Reduced 6.01%	2,345 $228,000
Q1 2020 May 08, 2020	BUY	$124.16 - $247.74 $6,208 - $12,387	50 Added 2.04%	2,495 $360,000
Q4 2019 Feb 04, 2020	BUY	$74.57 - $217.92 $182,323 - $532,814	2,445 New	2,445 $499,000

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account